Pernix Therapeutics Holdings Inc (NASDAQ:PTX)

4.29
Data as of Apr 15
 -0.11 / -2.50%
Today’s Change
1.68
Today|||52-Week Range
6.02
+70.24%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$182.7M

Company Description

Pernix Therapeutics Holdings, Inc. is a specialty pharmaceutical company, which is focused on the sales, marketing and development of branded and generic pharmaceutical products for the pediatric market. Its pediatric products are focused on allergy and upper respiratory, including nasal, chest congestion and cough, antibiotics, and dermatology. Pernix Therapeutics Holdings branded products CEDAX, an antibiotic for middle ear infections; NATROBA, which is a topical treatment for head lice; OMECLAMOX-PAK, a ten-day therapy of omeprazole delayed-release capsules, clarithromycin tablets and amoxicillin capsules for the treatment of helicobacter pylori infection and duodenal ulcer disease; and REZYST, which is a probiotic blend to promote dietary management. The company promotes its branded pediatric and generic products through its sales force wholly-owned subsidiary, Macoven Pharmaceuticals. Pernix Therapeutics Holdings was founded in November 1996 and is headquartered in The Woodlands, TX.

Contact Information

Pernix Therapeutics Holdings, Inc.
10003 Woodloch Forest Drive
The Woodlands Texas 77380
P:(832) 934-1825
Investor Relations:

Employees

Shareholders

Individual stakeholders31.65%
Other institutional25.14%
Mutual fund holders10.13%

Top Executives

Douglas L. DrysdaleChairman, President & Chief Executive Officer
Terence S. NovakChief Operating Officer
Tracy Simmons CliffordCFO, Secretary, Treasurer, CAO & Finance Director
Brian T. DorseySenior Vice President-Research & Development
Cooper C. CollinsChief Strategy Officer

To view my watchlist

Not a member yet?

Sign up now for a free account
Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer LIBOR Warning: Neither BBA Enterprises Limited, nor the BBA LIBOR Contributor Banks, nor Reuters, can be held liable for any irregularity or inaccuracy of BBA LIBOR. Disclaimer. Morningstar: © 2014 Morningstar, Inc. All Rights Reserved. Disclaimer The Dow Jones IndexesSM are proprietary to and distributed by Dow Jones & Company, Inc. and have been licensed for use. All content of the Dow Jones IndexesSM © 2014 is proprietary to Dow Jones & Company, Inc. Chicago Mercantile Association. The market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. FactSet Research Systems Inc. 2014. All rights reserved. Most stock quote data provided by BATS.